ReviewTranslational pediatrics2026
Recent advances in neonatal Beckwith-Wiedemann syndrome: from molecular diagnosis to multidisciplinary management-a narrative review.
Review in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Beckwith-Wiedemann syndrome (BWS) is a complex congenital overgrowth disorder resulting from genetic and epigenetic dysregulation at the 11p15.5 locus. It is clinically characterized by macrosomia, macroglossia, abdominal wall defects (e.g., omphalocele), refractory hypoglycemia, and an increased risk of embryonal tumors such as Wilms tumor (WT) and hepatoblastoma (HB). This review aims to synthesize recent advances in the molecular diagnosis, neonatal clinical management, and long-term surveillance of BWS, with the goal of providing evidence-based, multidisciplinary strategies to improve outcomes. Methods: This is a narrative review based on current literature and clinical guidelines. We integrated findings from recent studies on molecular diagnostics (including methylation-specific testing and uniparental disomy analysis), neonatal interventions, tumor surveillance protocols, and multidisciplinary care models for BWS. Key Content and Findings: Molecular subtyping now enables precise diagnosis and tumor risk stratification, guiding personalized care. In the neonatal period, critical issues such as hypoglycemia due to hyperinsulinism and airway compromise from macroglossia require specialized interventions [e.g., continuous glucose monitoring (CGM) and tongue-reduction surgery]. Meanwhile, omphalocele is addressed following standard surgical management approaches. Long-term care emphasizes structured tumor screening [abdominal ultrasound and serum alpha-fetoprotein (AFP)], growth and developmental monitoring, functional rehabilitation, and genetic counseling to address familial recurrence risks. Conclusions: The integration of molecular diagnostics with coordinated, multidisciplinary management significantly enhances early detection, acute care, and long-term outcomes in neonates with BWS. Future efforts should focus on refining risk-adapted screening protocols and advancing precision medicine approaches to further optimize care and quality of life for affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.